Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized trial of BI 685509 in progressive systemic sclerosis
jRCT2041220079Phase 2Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Mar 2023
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, double-blind trial in systemic sclerosis (SSc) comparing BI 685509 with Placebo (2 arms). Primary endpoint: Forced vital capacity (FVC). Started Mar 2023; status: completed.
02
Drugs
avenciguat
03
Conditions
systemic sclerosis (SSc)
Beyond the preview
Go deeper on jRCT2041220079.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2041220079.